HB1004 amends Maryland’s public health law on Alzheimer’s disease and related dementias to expand what the Maryland Department of Health must include in its outreach and education efforts. The Department, working with the Department of Aging, the Virginia I. Jones Alzheimer’s Disease and Related Dementias Council, and the Greater Maryland Chapter of the Alzheimer’s Association, must now add information on FDA-approved treatments for Alzheimer’s disease and related dementias, including how those treatments are used and what outcomes have been observed. The bill also broadens public education language to emphasize treatment, not just early detection and diagnosis, and to include information about treatment outcomes based on biological sex.
The bill also creates a new website requirement. In collaboration with the state-designated health information exchange, the Department must establish and maintain a publicly accessible website with downloadable data on the prevalence and hospitalization rate of Alzheimer’s disease and related dementias in Maryland. To the extent possible, the data must be broken down by age, sex, race, ethnicity, county, co-occurrence of Down syndrome (trisomy-21), and type of dementia, and it must include the most recent five-year period available as of September 30, 2025, with annual updates beginning in 2027.
In practical terms, the bill updates Section 18-110 of the Health-General Article and adds new Section 18-111. It expands the Department of Health’s duties in public outreach and data reporting, but it does not create a new benefit program or mandate direct clinical treatment coverage. Instead, it changes how the state educates providers and the public and how it publishes dementia-related data.
The overall sentiment appears strongly supportive. The bill passed both chambers with overwhelming margins, indicating broad bipartisan agreement on improving awareness, data transparency, and education around Alzheimer’s disease and related dementias. The absence of recorded committee transcript debate also suggests little visible controversy in the available record.
Any potential points of contention are limited and appear more policy-oriented than partisan. The bill’s emphasis on FDA-approved treatments, sex-based outcome information, and detailed demographic data could raise questions about data availability, implementation burden, and how the Department will interpret “to the extent possible,” but no specific opposition is reflected in the voting history provided.
HB1004 expands the Maryland Department of Health’s statutory responsibilities under Health-General §18-110 and adds new §18-111 requiring a public dementia data website. It affects the Department of Health, the Department of Aging, the Alzheimer’s Association, the Virginia I. Jones Alzheimer’s Disease and Related Dementias Council, and the state-designated health information exchange, while indirectly benefiting health care providers, patients, caregivers, and researchers by increasing access to treatment information and prevalence/hospitalization data.
The bill appears to have been received very positively. It passed the House 128-9 and the Senate 46-0, suggesting broad bipartisan support for Alzheimer’s education, treatment awareness, and public data reporting. No committee transcript discussion was provided, and the voting record indicates little to no organized opposition.
The main possible areas of contention are implementation details rather than the bill’s purpose. These include whether the Department can reliably collect and publish the requested demographic and county-level data, how much effort will be required to maintain the website and update it annually, and how the state will present information on FDA-approved treatments and sex-based outcomes. The bill text does not show any explicit opposition, and the strong vote totals suggest these concerns were not significant in the legislative process.